May 31,2022

OncoHealth and Blue Note Therapeutics Partner to Provide a Digital Therapeutic for Treating Cancer-Related Anxiety and Depression Symptoms

Blue Note Therapeutics, a prescription digital therapeutics (PDT) company dedicated to easing the burden of cancer and improving outcomes, and OncoHealth, a leading digital health company dedicated to oncology, have partnered to support patients coping with cancer by delivering oncology-specific mental health care. Through OncoHealth's telehealth platform, Iris™, licensed healthcare professionals will now provide Blue Note's attune™ to patients living with cancer. Blue Note developed attune as an “on-demand” self-directed tool for patients with cancer. 

COLLABORATION PARTNERSHIP

#institution

#pdt

View Analyst & Ambassador Comments
Go to original news
Jun 21,2022

Appalachian Regional Healthcare Selects Biofourmis Tech for Home Hospital Programs, Including Rural Healthcare Study

Biofourmis, a global leader in virtual care and digital medicine, today announced that Appalachian Regional Healthcare (ARH), based in Lexington, Ky., will be using Biofourmis’ technology to support a new program delivering acute hospital-level care inside patients’ homes, including a clinical trial studying this care model in rural areas.

COLLABORATION PARTNERSHIP

#institution

#rpm

#virtual care

View Analyst & Ambassador Comments
Go to original news
Jul 25,2022

First-of-its-kind partnership provides free access to digital mental health treatments for all newly diagnosed cancer patients in the United Kingdom

Newly diagnosed cancer patients across the United Kingdom (UK) are now able to easily access innovative and effective treatments to support their mental health thanks to a new partnership between Macmillan Cancer Support and digital therapeutics company Big Health, makers of Sleepio and Daylight. The partnership between Macmillan and Big Health will provide newly diagnosed cancer patients aged 18 and older residing in England, Wales, and Northern Ireland free access to Sleepio for insomnia and Daylight for anxiety to manage their mental health needs.

COLLABORATION PARTNERSHIP

#institution

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 03,2022

Pear Therapeutics And Cove Behavioral Health To Provide Patients Access To Prescription Digital Therapeutic For The Treatment Of Opioid Use Disorder

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), announced today that Cove Behavioral Health, Inc. (“Cove”) will provide access to Pear’s FDA-authorized PDT reSET-O® for the treatment of opioid use disorder (OUD). Cove, a comprehensive community-based substance use disorder service provider, is implementing reSET-O® in its centers in Tampa Bay, Florida for eligible patients. Funding is provided by the State Opioid Response (SOR) grant, administered by Central Florida Behavioral Health Network, and part of the U.S. Department of Health and Human Services’ Substance Abuse and Mental Health Services Administration (SAMHSA) SOR grant program for people in need of prevention, treatment and recovery support for OUD.

COLLABORATION PARTNERSHIP

#institution

#pdt

#cbt

View Analyst & Ambassador Comments
Go to original news
Aug 30,2022

Hygieia adds Metro Detroit Endocrinology Center as clinical partner for its d-Nav® Insulin Management Program

Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav® network and makes autonomous insulin therapy service available for an underserved population.

COLLABORATION PARTNERSHIP

#institution

#software

View Analyst & Ambassador Comments
Go to original news
Sep 01,2022

South Carolina Department Of Corrections And Pear Therapeutics Team Up To Support Inmates In Recovery From Substance Use Disorders

The S.C. Department of Corrections (SCDC) today announced a plan with Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), to offer FDA-authorized PDTs to support women inmates in recovery from opioid and other substance use disorders. This first of its kind collaboration in a correctional setting supports SCDC’s commitment to leverage innovative treatment options to provide care for individuals seeking recovery. Eligible patients at the Camille Griffin Graham Correctional Institution will be prescribed and treated with reSET® or reSET-O® to help the facility expand access to addiction services. This project is funded by the S.C. Department of Alcohol and Other Drug Abuse Services.

COLLABORATION PARTNERSHIP

#institution

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 07,2022

Orexo’s partner Trinity Health today announces the availability of vorvida® and deprexis® to patients

Orexo AB today announces the Integrated Healthcare System, Trinity Health in North Dakota, in partnership with Orexo, is expanding patient access to digital therapeutics. Trinity Health will now offer Orexo’s evidence-based digital therapies vorvida® and deprexis® to help patients manage depression and excessive drinking. During the last year, Orexo and Trinity Health have collaborated to establish new administrative processes and support systems to ensure effective patient access to these innovative digital therapies and reimbursement of the products through a collaborative care model.

COLLABORATION PARTNERSHIP

#institution

#cbt

#reimbursement

View Analyst & Ambassador Comments
Go to original news
Sep 12,2022

Hygieia adds clinical partners in New York and North Carolina to itsd-Nav® Insulin Management Program

Hygieia, a provider of digital therapeutics for insulin management, has added Endocrine Associates of West Village P.C. in Manhattan and Long Island City, NY, and Physicians East in Greenville, NC, as clinical partners. The partnerships are the first in their respective states and make Hygieia’s d-Nav® autonomous insulin therapy service available to more patients with advanced type 2 diabetes.

COLLABORATION PARTNERSHIP

#institution

#software

View Analyst & Ambassador Comments
Go to original news
Sep 15,2022

Big Health Digital Therapeutics Daylight and Sleepio Selected for Evernorth Digital Health Formulary

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, today announced that Daylight for anxiety and Sleepio for insomnia have been added to the Evernorth Digital Health Formulary. By extending access to Daylight and Sleepio to employers and health plans through Evernorth’s Digital Health Formulary, more patients will have access to safe, effective evidence-based solutions for anxiety and insomnia. Daylight and Sleepio can be used alongside medications or as a clinical grade alternative to medications, or when talk therapy is not accessible.

COLLABORATION PARTNERSHIP

#institution

View Analyst & Ambassador Comments
Go to original news
Sep 20,2022

Rightway Introduces RightwayHub to Centralize Access to Leading Healthcare Solutions like Sword Health, Vida Health, and More

Rightway, a company revolutionizing care navigation and pharmacy benefits, today announced the launch of its ecosystem partnership program, RightwayHub, which seeks to streamline access to leading healthcare solutions. The program brings together a range of vetted programs, such as Vida Health and SWORD Health, that together reflect a comprehensive benefits strategy across priority condition areas including musculoskeletal health, behavioral health, chronic care management, and more.

COLLABORATION PARTNERSHIP

#institution

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Subscribe to INSTITUTION